Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720–826.

Article  CAS  PubMed  Google Scholar 

Sanderson NC, Parker WAE, Storey RF. Ticagrelor: clinical development and future potential. Rev Cardiovasc Med. 2021;22:373–94.

Article  PubMed  Google Scholar 

Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038–47.

Article  CAS  PubMed  Google Scholar 

Wen M, Li Y, Qu X, Zhu Y, Tian L, Shen Z, Yang X, Shi X. Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis. BMC Cardiovasc Disord. 2020;20:430.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lemesle G, Schurtz G, Bauters C, Hamon M. High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis. J Thromb Haemost. 2015;13:931–42.

Article  CAS  PubMed  Google Scholar 

Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.

Article  CAS  PubMed  Google Scholar 

Verdoia M, Sartori C, Pergolini P, Nardin M, Rolla R, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G. Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation. Vascul Pharmacol. 2016;77:48–53.

Article  CAS  PubMed  Google Scholar 

Gutmann C, Joshi A, Zampetaki A, Mayr M. The Landscape of Coding and noncoding RNAs in platelets. Antioxid Redox Signal. 2021;34:1200–16.

Article  CAS  PubMed  Google Scholar 

Inzulza-Tapia A, Alarcón M. Role of non-coding RNA of human platelet in Cardiovascular Disease. Curr Med Chem. 2022;29:3420–44.

Article  CAS  PubMed  Google Scholar 

Alhasan AA, Izuogu OG, Al-Balool HH, Steyn JS, Evans A, Colzani M, Ghevaert C, Mountford JC, Marenah L, Elliott DJ, et al. Circular RNA enrichment in platelets is a signature of transcriptome degradation. Blood. 2016;127:e1–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Preußer C, Hung LH, Schneider T, Schreiner S, Hardt M, Moebus A, Santoso S, Bindereif A. Selective release of circRNAs in platelet-derived extracellular vesicles. J Extracell Vesicles. 2018;7:1424473.

Article  PubMed  PubMed Central  Google Scholar 

Li X, Yang L, Chen LL. The Biogenesis, functions, and challenges of Circular RNAs. Mol Cell. 2018;71:428–42.

Article  CAS  PubMed  Google Scholar 

The database is freely accessible. through the web server at http://circinteractome.nia.nih.gov.Accessed 11 Nov. 2023.

Lv J, Li K, Yu H, Han J, Zhuang J, Yu R, Cheng Y, Song Q, Bai K, Cao Q, et al. HNRNPL induced circFAM13B increased bladder cancer immunotherapy sensitivity via inhibiting glycolysis through IGF2BP1/PKM2 pathway. J Exp Clin Cancer Res. 2023;42:41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ning L, Long B, Zhang W, Yu M, Wang S, Cao D, Yang J, Shen K, Huang Y, Lang J. Circular RNA profiling reveals circEXOC6B and circN4BP2L2 as novel prognostic biomarkers in epithelial ovarian cancer. Int J Oncol. 2018;53:2637–46.

CAS  PubMed  Google Scholar 

Xie Y, Hang X, Xu W, Gu J, Zhang Y, Wang J, Zhang X, Cao X, Zhan J, Wang J, Gan J. CircFAM13B promotes the proliferation of hepatocellular carcinoma by sponging miR-212, upregulating E2F5 expression and activating the P53 pathway. Cancer Cell Int. 2021;21:410.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zou Y, Wang Y, Wu Y, Zhang S, Liu H, Yin T. Prediction of residual ischemic risk in ticagrelor-treated patients with acute coronary syndrome. Thromb J. 2022;20:21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gurbel PA, Bliden KP, Navickas IA, Mahla E, Dichiara J, Suarez TA, Antonino MJ, Tantry US, Cohen E. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J. 2010;160:346–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol. 2007;49:657–66.

Article  CAS  PubMed  Google Scholar 

Siller-Matula JM, Akca B, Neunteufl T, Maurer G, Lang IM, Kreiner G, Berger R, Delle-Karth G. Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor. Platelets. 2016;27:373–7.

Article  CAS  PubMed  Google Scholar 

Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2012;5:797–804.

Article  CAS  PubMed  Google Scholar 

Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, et al. Ticagrelor or Prasugrel in patients with Acute Coronary syndromes. N Engl J Med. 2019;381:1524–34.

Article  PubMed  Google Scholar 

Turgeon RD, Koshman SL, Youngson E, Har B, Wilton SB, James MT, Graham MM. Association of Ticagrelor vs clopidogrel with major adverse coronary events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. JAMA Intern Med. 2020;180:420–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Larmore C, Effron MB, Molife C, DeKoven M, Zhu Y, Lu J, Karkare S, Lieu HD, Lee WC, Vetrovec GW. Real-world comparison of prasugrel with ticagrelor in patients with acute coronary syndrome treated with percutaneous coronary intervention in the United States. Catheter Cardiovasc Interv. 2016;88:535–44.

Article  PubMed  Google Scholar 

Effron MB, Nair KV, Molife C, Keller SY, Page RL 2nd, Simeone JC, Murphy B, Nordstrom BL, Zhu Y, McCollam PL. Vetrovec GW: one-year clinical effectiveness comparison of prasugrel with ticagrelor: results from a retrospective observational study using an integrated claims database. Am J Cardiovasc Drugs. 2018;18:129–41.

Article  CAS  PubMed  Google Scholar 

Han Y, Claessen BE, Chen SL, Chunguang Q, Zhou Y, Xu Y, Hailong L, Chen J, Qiang W, Zhang R, et al. Ticagrelor with or without aspirin in Chinese patients undergoing percutaneous coronary intervention: a twilight China substudy. Circ Cardiovasc Interv. 2022;15:e009495.

Article  CAS  PubMed  Google Scholar 

Krammer TL, Mayr M, Hackl M. microRNAs as promising biomarkers of platelet activity in antiplatelet therapy monitoring. Int J Mol Sci 2020, 21.

Jansen F, Yang X, Proebsting S, Hoelscher M, Przybilla D, Baumann K, Schmitz T, Dolf A, Endl E, Franklin BS, et al. MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease. J Am Heart Assoc. 2014;3:e001249.

Article  PubMed  PubMed Central  Google Scholar 

Czajka P, Fitas A, Jakubik D, Eyileten C, Gasecka A, Wicik Z, Siller-Matula JM, Filipiak KJ, Postula M. MicroRNA as potential biomarkers of platelet function on antiplatelet therapy: a review. Front Physiol. 2021;12:652579.

Article  PubMed  PubMed Central  Google Scholar